A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...

(RTTNews) - Palatin Technologies, Inc. (PTN) Friday reported positive topline results from its Phase 2 study of PL8177 in patients with active ulcerative colitis (UC), a form of inflammatory bowel ...

The study, focusing on safety, tolerability, and efficacy, showed that 33% of patients treated with PL8177 achieved clinical remission compared to none on placebo after eight weeks. According to ...

Topline results from our Phase 2 clinical study of PL8177 oral formulation for the treatment of UC expected later this quarter. Diabetic nephropathy Phase 2B study in patients with Type 2 diabetic ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...

A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin Technologies’ melanocortin-1 receptor (MC1R) agonist, PL8177. The company ...

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $18.2 million, has announced encouraging results from its Phase 2 trial of ...

Topline results from our Phase 2 clinical study of PL8177 oral formulation for the treatment of UC expected later this quarter. Diabetic nephropathy Phase 2B study in patients with Type 2 diabetic ...